How to Differentiate and Treat Cystic Laesions in the Anterior Mediastinum (DETECTION)
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Apr 20, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The DETECTION trial is a clinical study looking at how to identify and treat cysts located in the front part of the chest, known as the anterior mediastinum. These cysts can be of different types, including thymic cysts, bronchogenic cysts, and pericardial cysts. The study is currently recruiting participants aged 65 to 74 years, and it is open to both men and women who have been diagnosed with one of these cysts through medical imaging.
If you join this trial, you can expect to undergo various tests and assessments to help doctors better understand these cysts and how to treat them. It’s important to note that individuals under 18 years old or those who do not have the necessary imaging approved for follow-up are not eligible to participate. This study aims to improve the way we manage these types of cysts, potentially leading to better treatment options in the future.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: cysts in the anterior mediastinum
- • Thymic cysts
- • Bronchogenic cysts
- • Pericardial cysts
- • Cystic thymoma
- • Cystic teratoma
- Exclusion Criteria:
- • Patients \<18 years old
- • Patients without radiological imaging
- • Patients without approval for follow-up
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported